Results 71 to 80 of about 23,280 (257)

Efficacy and safety of oral semaglutide with flexible dose adjustment versus sitagliptin in type 2 diabetes (PIONEER 7): a multicentre, open-label, randomised, phase 3a trial.

The Lancet Diabetes and Endocrinology, 2019
BACKGROUND Oral semaglutide is the first oral formulation of a glucagon-like peptide-1 (GLP-1) receptor agonist developed for the treatment of type 2 diabetes.
T. Pieber, B. Bode, A. Mertens, Young Min Cho, E. Christiansen, Christin L. Hertz, S. Wallenstein, J. B. Buse, S. Akın, N. Aladağ, A. Arif, L. Aronne, S. Aronoff, E. Ataoglu, S. Baik, H. Bays, P. Beckett, D. Berker, S. Bilz, B. Bode, E. Braun, J. Buse, L. Canani, Y. M. Cho, C. Chung, I. Colin, J. Condit, J. Cooper, B. Delgado, D. C. Eagerton, I. N. El Ebrashy, M. E. El Hefnawy, F. G. Eliaschewitz, M. P. Finneran, S. Fischli, E. Fließer-Görzer, J. Geohas, N. Godbole, A. Golay, S. Gorban de Lapertosa, J. Gross, H. Gulseth, F. Helland, H. O. Høivik, C. Issa, E. S. Kang, C. Keller, S. A. Khalil, N. Kim, I. J. Kim, L. J. Klaff, M. Laimer, J. C. LaRocque, S. Lederman, Kwang-Woo Lee, W. R. Litchfield, M. Manning, A. Mertens, E. J. Morawski, A. Murray, P. Nicol, T. O'Connor, A. Oguz, S. Ong, A. Özdemir, E. M. Palace, B. A. Palchick, J. Pereles-Ortiz, T. Pieber, R. Prager, V. Preumont, E. Riffer, L. Rista, G. Rudofsky, R. Sari, A. Scheen, B. Schultes, J. Seo, S. Shelbaya, K. Sivalingam, C. H. Sorli, S. Stauble, D. A. Streja, G. T'Sjoen, T. Tetiker, L. V. van Gaal, C. Vercammen, M. Warren, D. L. Weinstein, D. Weiss, A. White, M. Winnie, C. Wium, D. Yavuz   +93 more
semanticscholar   +1 more source

Dipeptidyl peptidase-4 (DPP4) inhibitor sitagliptin alleviates liver inflammation of diabetic mice by acting as a ROS scavenger and inhibiting the NFκB pathway

Cell Death Discovery, 2021
As a common chronic metabolic disease, the development of diabetes mellitus (DM) may also be accompanied by liver damage and inflammatory disorders. Sitagliptin is an inhibitor of dipeptidyl peptidase-4 (DPP4, also known as CD26), which is clinically ...
Xin Wang, Jing Ke, Ying-Chun Zhu, Bin Cao, Rui-Li Yin, Yan Wang, Ling Wei, Li-jie Zhang, Long-Yan Yang, Dong Zhao   +9 more
semanticscholar   +1 more source

Six-Year Complete Remission of Type-1 Diabetes Mellitus in an Adult Treated With Sitagliptin [PDF]

, 2023
A "honeymoon" phase is a transient period of type 1 diabetes (T1D) remission, characterized by a significant reduction in insulin requirements and good glycemic control due to a temporary restoration of pancreatic β-cell function.
Benido Silva, Vânia, Pereira, Maria Teresa   +1 more
core   +1 more source

Ipragliflozin and sitagliptin differentially affect lipid and apolipoprotein profiles in type 2 diabetes: the SUCRE study

Cardiovascular Diabetology
SGLT2 inhibitors and DPP4 inhibitors have been suggested to affect lipid metabolism. However, there are few randomized controlled trials comparing the effects on the lipid metabolism between the two types of antidiabetic drugs.
Mototsugu Nagao, Jun Sasaki, Kyoko Tanimura-Inagaki, I. Sakuma, Hitoshi Sugihara, Shinichi Oikawa   +5 more
semanticscholar   +1 more source

Liraglutide, Sitagliptin, and Insulin Glargine Added to Metformin: The Effect on Body Weight and Intrahepatic Lipid in Patients With Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease

Hepatology, 2019
To investigate the effect of antidiabetic agents on nonalcoholic fatty liver disease (NAFLD) in patients with type 2 diabetes mellitus (T2DM), 75 patients with T2DM and NAFLD under inadequate glycemic control by metformin were randomized (1:1:1) to ...
Jin-Hua Yan, B. Yao, H. Kuang, Xu-Bin Yang, Qin Huang, Tianpei Hong, Yu-Shu Li, Jing-Tao Dou, Wen-Ying Yang, G. Qin, Hui-Juan Yuan, Xinhua Xiao, Si-Hui Luo, Z. Shan, Hong-Rong Deng, Ying Tan, Fen Xu, Wen Xu, L. Zeng, Z. Kang, J. Weng   +20 more
semanticscholar   +1 more source

Vesicles of yeast cell wall-sitagliptin to alleviate neuroinflammation in Alzheimer's disease.

Nanomedicine: Nanotechnology, Biology and Medicine, 2022
A cell-based drug delivery system based on yeast-cell wall loaded with sitagliptin, a drug with an anti-inflammatory effect, was developed to control neuroinflammation associated with Alzheimer's disease. The optimized nanoparticles had a spherical shape
N. Mozafari, A. Dehshahri, H. Ashrafi, S. Mohammadi-Samani, M. Shahbazi, R. Heidari, N. Azarpira, A. Azadi   +7 more
semanticscholar   +1 more source

Deprotektive Alkylierung: Eine Plattform zur Umsetzung von Alkoholen zu Aminen mittels Nonafluormesitylensulfonamiden

Angewandte Chemie, EarlyView.
Die direkte Umwandlung von Alkoholen in tertiäre oder sekundäre Amine in einem Reaktionsschritt unter Verwendung von Nms‐Amiden wird beschrieben. Die Transformation zeichnet sich durch eine breite Toleranz gegenüber verschiedenen funktionellen Gruppen und eine hohe Stereospezifität aus, was ihre Eignung für die Synthese isotopenmarkierter Arzneimittel ...
Jakub Brześkiewicz, Kunj Kapur, Boris Maryasin, Nuno Maulide   +3 more
wiley   +1 more source

Analysis of published and unpublished sitagliptin (Januvia) studies in humans

, 2014
August 25, 2014 5 pm Bogotá time zone Sitagliptin (Januvia) ClinicalTrials.gov records completed before Jan 2011. Total number of records = 115Expert search terms (PubMed): http://goo.gl/pIdDaQ Records not found = 85Results = 40 Expert search terms of ...
Jorge H Ramirez (587826)
core   +1 more source

Efficacy and safety of sitagliptin in elderly patients with type 2 diabetes mellitus: A focus on hypoglycemia

Journal of Diabetes Investigation, 2019
Aims/Introduction To investigate the efficacy and safety of sitagliptin in elderly patients with type 2 diabetes mellitus, with a focus on hypoglycemia.
Masahiro Fukuda, Kunihiro Doi, Masahiro Sugawara, Koichi Mochizuki   +3 more
doaj   +1 more source

Sitagliptin 100 mg vs glimepiride 1–3 mg as an add-on to insulin and metformin in type 2 diabetes (SWIM)

Endocrine Connections, 2017
Objective: To compare the effect of sitagliptin (100 mg) vs glimepiride (1–3 mg) as add-on therapy in Indian type 2 diabetes (T2DM) patients on treatment with insulin and metformin (SWIM study).
Jothydev Kesavadev, Pradeep Babu Sadasivan Pillai, Arun Shankar, Gopika Krishnan, Sunitha Jothydev   +4 more
doaj   +1 more source